December 6, 2023
`Christine Nichols Kay, M.D.
`(Maiden name: Christine Michelle Nichols)
`DOB: 08-09-1979
`
`Vitreoretinal Associates
`4340 Newberry Road
`Suite 202
`Gainesville, FL 32607
`
`EDUCATION
`
`2009-2011
`
`University of Iowa, Iowa City, IA
`Vitreoretinal Surgery Fellowship
`
`Christine Kay, M.D.
`December 6, 2023
`
`PO Box 674
`McIntosh, FL 32664
`813-500-9725
`
`Summer 2009
`
`Bascom Palmer Eye Institute, Miami, FL; Visiting Fellow under
`mentorship of Dr. Harry Flynn
`
`2006–2009
`
`2005-2006
`
`2001–2005
`
`1998–2001
`
`Summer 1999
`
`1997–1998
`
`1994-1997
`
`University of South Florida, Tampa, FL
`Ophthalmology Residency
`
`Roanoke Carilion Memorial Hospital, Roanoke, V
`Transitional Internship
`
`University of Florida, Gainesville, FL
`Doctor of Medicine, May 2005
`
`Harvard University, Cambridge, MA
`Bachelor of Arts in Neurobiology; magna cum laude
`
`Oxford University, Oxford, England
`Study Abroad program in English Literature
`
`Duke University, Durham, NC
`Bachelor of Arts Candidate
`
`Bloomingdale Senior High School, Valrico, FL
`Valedictorian
`
`1
`
`Celltrion Exhibit 1003
`Page 1
`
`

`

`December 6, 2023
`
`CERTIFICATIONS
`
`2003
`2004
`2005
`2010
`2010
`
`LICENSES
`
`State
`Florida
`Iowa
`
`
`USMLE, Part I
`USMLE, Part II Clinical Knowledge
`USMLE Part II Clinical Skills and USMLE Part III
`American Board of Ophthalmology Written exam – Passed
`American Board of Ophthalmology Oral exam – Passed
`
`Number
`ME99947
`38258
`
`Type
`Permanent
` Permanent
`
`Issued
`9/08/2007
`2/20/2009
`
`Expires
`1/31/2024
`8/01/2011
`
`PROFESSIONAL POSITIONS
`9/14-present
`9/14-present
`9/14-present
`
`2020-present
`2023-present
`2022-present
`2022-present
`2018-present
`2018-2020
`2021-2021
`2020-present
`2017-2020
`8/11-8/2014
`
`9/13-present
`
`10/14-present
`
`Vitreoretinal Associates; Gainesville, Florida; Shareholder/Partner
`North Florida Surgical Pavilion
`Affiliate Assistant Professor in the Department of Ophthalmology at the
`University of South Florida; Tampa, Florida
`Clinical Ophthalmology Advisor/consultant for Atsena Therapeutics
`Consultant for Kiora Pharmaceuticals
`Consultant for Kodiak
`Consultant for Ascidian Therapeutics
`Consultant for Novartis
`Consultant for Astellas
`Consultant for 4D Therapeutics
`Consultant for Foundation Fighting Blindness
`Speaker’s Bureau and Consultant for Spark Therapeutics
`Assistant Professor in Department of Ophthalmology,
`Vitreoretinal Surgery, University of Florida.
`Director Vitreoretinal surgical service
`Vitreoretinal fellowship director,
`Director electrophysiology service
` Director, Vitreoretinal service
`Independent Medical Safety Monitor (IMSM) for the New
`Enrollment Post-Approval Study of the Argus® II Retinal
`Prosthesis System
`Member of Data Safety Monitor Board for Phase 2 Choroideremia Gene
`Therapy Clinical Trial, ClinicalTrials.gov identifier: NCT02553135
`
`2
`
`Celltrion Exhibit 1003
`Page 2
`
`

`

`December 6, 2023
`
`7/07–6/09
`
`7/03-8/03
`
`5/00-8/00
`
`1999-2001
`
`1999-2001
`
`1998
`
`1997
`
`
`
`
`
`HONORS AND AWARDS
`2018
`2017
`2017
`2012
`2008-2009
`2009
`
` 2008
`
`2007
`
`2002
`2001
`
`2000
`2000
`1998
`1998
`1998
`1997
`
`Fee Basis Ophthalmologist
`James A. Haley Veterans Administration; Tampa, FL
`Summer Intern, Public Speaker for Cardiovascular Health
`Northeast Florida AHEC; Jacksonville, FL
`Research Intern
`Mass General Hospital; Cambridge, MA
`Multi-Disciplinary Institute for Neuropsychological
`Development Intern; Cambridge, MA
`Organic Chemistry and Physics Tutor
`Harvard Bureau of Study Council; Cambridge, MA
`Howard Hughes Research Fellow
`Duke University; Durham, NC
`Ophthalmic technician
`Brandon Cataract Center and Eye Clinic; Brandon, FL
`
`ASRS Senior Honor Award
`Inducted into Macula Society
`Inducted into Retina Society
`Honor Award, American Society of Retina Specialists
`Chief Resident, USF Ophthalmology residency
`USF Health Science Research Day: Outstanding Poster in Clinical
`Studies and Case Reports
`2nd Place at Florida Society of Ophthalmology Resident Research
`Symposium
`
`Arnold P. Gold Foundation Humanism and Excellence in
`Teaching Award – Carilion Roanoke Memorial Hospital
`Alpha Omega Alpha Research Award
`Harvard Hoopes Prize/Scholarship for Excellent Senior Honors
`Thesis
`Harvard College Scholarship (merit based)
`Harvard College Research Program Grant for neuroscience research
`Phi Eta Sigma Honor Society, Duke University
`Dean’s List with Distinction, Duke University
`Howard Hughes Research Grant for undergraduate research
`Valedictorian; Bloomingdale High School, Brandon, FL
`
`Editorial Roles:
`Ophthalmic Surgery Lasers and Imaging: Retina
`RETINA
`PLoS One
`IVOS
`Human Mutation
`
`GRANTS/RESEARCH EXPERIENCE
`2023-present
`Phase 3 Oral N-Acetyalcysteine for Retinitis Pigmentosa (NAC Attack)
`
`3
`
`Celltrion Exhibit 1003
`Page 3
`
`

`

`December 6, 2023
`
`trial
`Sponsor: NEI
`Role: PI
`NCT: 05537220
`
`2021-present
`
`2021-present
`
`2021-present
`
`2021-present
`
`2021-present
`
`Phase 3 Randomized, Controlled Study of AAV5-RPGR for the Treatment
`of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR
`Gene
`Sponsor: MeiraGTx/Janssen
`Role: Principal Investigator/Surgeon
`NCT: 04671433
`
`EXPLORE: A Phase II, Outcomes Assessor-masked, Multicentre,
`Randomised Study to Evaluate the Safety and Efficacy of Two Doses of
`GT005 Administered as a Single Subretinal Injection in Subjects
`With Geographic Atrophy Secondary to Age-related Macular
`Degeneration.
`Sponsor: Gyroscope
`Role: Principal Investigator/Surgeon
`NCT: NCT04437368
`
`HORIZON: A Phase II, Open-label, Outcomes-assessor Masked,
`Multicentre, Randomised, Controlled Study to Evaluate the Safety and
`Efficacy of Two Doses of GT005 Administered as a Single Subretinal
`Injection in Subjects With Geographic Atrophy Secondary to Age-related
`Macular Degeneration
`Sponsor: Gyroscope
`Role: Principal Investigator/Surgeon
`NCT: NCT04566445
`
`A Phase 2, Open-label Study to Explore the Pharmacodynamics of Two
`Doses in Two Formulations of RGX-314 Gene Therapy Administered Via
`Subretinal Delivery in Participants With Neovascular Age-related Macular
`Degeneration
`Sponsor: Regenxbio
`NCT: NCT04832724
`Role: Principal Investigator/Surgeon
`
`A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to
`Aflibercept in Participants With Diabetic Macular Edema (DME).
`Sponsor: Kodiak
`NCT: NCT04611152
`Role: Principal Investigator
`
`2021-present
`
`A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to
`
`4
`
`Celltrion Exhibit 1003
`Page 4
`
`

`

`December 6, 2023
`
`2020-present
`
`2020-present
`
`2019-present
`
`2019-present
`
`2018-2019
`
`2017-present
`
`2016-present
`
`Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
`Sponsor: Kodiak
`NCT: NCT04592419
`Role: Principal Investigator
`
`A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled
`Clinical Trial to Assess the Safety and Efficacy of Intravitreal
`Administration of Zimura (Complement C5 Inhibitor) in Patients
`With Geographic Atrophy Secondary to Age-Related Macular
`Degeneration.
`Sponsor: Kodiak
`NCT: NCT04435366
`Role: Principal Investigator
`
`A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With
`Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in
`the RHO Gene.
`Sponsor: ProQR Therapeutics
`NCT: NCT04123626
`Role: Principal Investigator
`
`Phase 3 study of Alk-001 in Geographic Atrophy (SAGA)
`Sponsor: Alkeus
`NCT: 03845582
`Role: Principal Investigator
`A clinical trial of retinal gene therapy for X-linked retinitis pigmentosa
`(XIRIUS)
`Sponsor: Nightstar Therapeutics
`ClinicalTrials.gov Identifier: NCT03116113
`Role: Principal investigator/Surgeon
`
`Zimura compared to sham in patients with autosomal recessive
`Stargardt disease (STGD1)
`Sponsor: Ophthotech
`NCT03364153
`Role: Principal Investigator
`
`Rate of Progression in USH2A related Retinal Degeneration (RUSH2A)
`Sponsor: Jaeb Center for Health Research
`
`Clinical Trials Identifier: NCT03146078
`Role: Principal Investigator
`
`Phase 1/2 Safety and Efficacy Trial of AAV Gene Therapy in Patients
`with CNGB3 Achromatopsia
`Sponsored by AGTC
`Role: Principal Investigator
`ClinicalTrials.gov identifier: NCT02599922
`
`5
`
`Celltrion Exhibit 1003
`Page 5
`
`

`

`December 6, 2023
`
`2016-present
`
`2015-present
`
`2013-2016
`
`2016
`
`Phase 1/2 Safety and Efficacy Trial of AAV Gene Therapy in Patients
`with CNGA3 Achromatopsia
`Sponsored by AGTC
`Role: Principal Investigator
`
`Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease.
`Sponsored by Alkeus. (September 2015 – present)
`Role: Principal Investigator.
`ClinicalTrials.gov identifier: NCT02402660
`
`Clinical and genetic characterization of individuals with achromatopsia.
`Sponsored by NEI and AGTC.
`Role: Principal Investigator.
`ClinicalTrials.gov identifier: NCT01846052
`
`Phase 2 Study of the Efficacy and Safety of QLT091001 in Subjects with
`Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment
`Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransferase
`(LRAT).
`Sponsor: QLT
`Role: Principal Investigator - completed site startup, however trial was
`suspended by sponsor before enrollment.
`
`2011-2016
`
`Foundation Fighting Blindness, Career Development Award
`(August 1, 2011 – July 31, 2016).
`Role: Principal Investigator.
`
`2013-2014
`
`2013-2014
`
`Total five year award amount: $375,000. Co-sponsors: Edwin Stone,
`M.D. Ph.D. and William Hauswirth, Ph.D. “Development and
`optimization of a viral gene delivery system for the treatment of
`CNGB3-associated Achromatopsia.”
`University of Florida/Vitreoretinal Associates
`
`NIH sponsored study: Vascular Reparative Mechanism by ACE2/Ang-
`(1-7) in Diabetes.
`9/1/11 – 6/30/16 ($914,139)
`(Co-PI of Clinical Trial component of study.)
`Principal Investigators: Dr. Grant and Dr. Raizada
`University of Florida.
`
`A Randomized, Double-masked, Placebo-controlled Study of the Safety
`and Efficacy of Gevokizumab in the Treatment of Active Non-infectious
`Intermediate, Posterior, or Pan-Uveitis.(Eyeguard A Study) Sponsor:
`XOMA.
`(4/11/2013-4/11/2017) ($61,092) 0.12 calendar months
`(Role: Principal Investigator.) University of Florida.
`
`6
`
`Celltrion Exhibit 1003
`Page 6
`
`

`

`December 6, 2023
`
`2011-2014
`
`2009-2011
`
`2009-2011
`
`2009-2011
`
`2007-2009
`
`2004-2005
`
`1999-2001
`
`1997-1998
`
`Toxicology studies for LHON AAV therapy. (Board-certified
`ophthalmologist performing safety fundus exams on treated rats post-
`AAV therapy.)
`University of Florida.
`
`Optical coherence tomography in Best disease: using imaging
`modalities to understand disease pathogenesis.
`Faculty Sponsor: Edwin Stone, M.D., Ph.D.
`University of Iowa.
`
`VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD
`(VIEW 1).
`(Sub-investigator).
`University of Iowa.
`
`Comparison of AMD Treatments Trials (CATT).
`(Sub-investigator.)
`University of Iowa.
`
`
`
`Digital Interference Holography in Ophthalmology
`Faculty Sponsor: Myung Kim, Ph.D. and David Richards, M.D.
`University of South Florida, Department of Physics
`
`The effect of silicone oil on intraocular pressure
`Faculty Sponsor: R. Ratnakaram, M.D.
`University of Florida, Department of Ophthalmology
`
`“The expression of alpha-Synuclein in Dementia with Lewy
`Bodies”
`Faculty Sponsor: Anne Young, M.D., Ph.D., Harvard College
`Harvard undergraduate neurobiology honors tract thesis
`Mass General Hospital; Boston, MA
`
`Neurobiology research: the effect of neurotrophic factors in
`ferret visual cortex
`Faculty Sponsor: Donald Lo, Ph.D., Duke University
`Duke University Bryan Research Center; Durham, NC
`
`CONSULTING POSITIONS:
`Atsena Therapeutics - consultant
`Kodiak – consultant
`Kiora - consultant
`Ascidian Therapeutics - consultant
`Astellas - consultant
`Sanofi – Advisory board meeting participant (AAO 2018)
`NightStar Therapeutics- Advisory Board (AAO 2018)
`Novartis – consultant
`4D Therapeutics - consultant
`Spark Therapeutics – consultant
`
`7
`
`Celltrion Exhibit 1003
`Page 7
`
`

`

`December 6, 2023
`
`Choroideremia Bascom Palmer trial – Data Safety Monitor
`Second Sight (ARGUS2) – Independent Medical Safety Monitor
`
`VISITING FELLOWSHIPS IN INHERITED RETINAL DISEASE
`1) Byron Lam, Bascom Palmer Eye Institute; Miami, Florida (May 2012)
`2) Gerry Fishman, Lighthouse for the Blind; Chicago, Illinois (September 2012)
`3) Dick Weleber, Casey Eye Institute; Portland, Oregon (May 2013)
`4) Isabelle Audo, Paris Eye Institute, Paris France (October 2013)
`
`
`
`PUBLICATIONS (peer-reviewed)
`[In print or forthcoming]
`
`Samuel G. Jacobson, Artur V. Cideciyan, Allen C. Ho, Alejandro J. Roman, Vivian Wu, Alexandra V. Garafalo,
`Alexander Sumaroka, Arun K. Krishnan, Malgorzata Swider, Abraham A. Mascio, Christine N. Kay, Dan Yoon,
`Kenji P. Fujita, Sanford L. Boye, Igor V. Peshenko, Alexander M. Dizhoor, Shannon E. Boye. Night vision restored
`in days after decades of congenital blindness. iScience, 2022
`
`Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA,
`Salabarria S, Corti M, Byrne BJ, Tremblay JP. Current Clinical Applications of In Vivo Gene Therapy with
`AAVs. Mol Ther. 2021 Feb 3;29(2):464-488.
`
`Gregori NZ, Hussain RM, Kay CN, Lam BL, Dermer H, Davis JL. Current Concepts and Emerging Gene
`Therapies for Inherited Retinal Diseases. Int Ophthalmol Clin. 2019 Winter;59(1):83-110.
`
`Duncan JL, Liang W, Maguire MG, Audo I, Ayala AR, Birch DG, Carroll J, Cheetham JK, Esposti SD, Durham
`TA, Erker L, Farsiu S, Ferris FL 3rd, Heon E, Hufnagel RB, Iannaccone A, Jaffe GJ, Kay CN, Michaelides M,
`Pennesi ME, Sahel JA; Foundation Fighting Blindness Consortium Investigator Group. Baseline Visual Field
`Findings in the RUSH2A Study: Associated Factors and Correlation With Other Measures of Disease
`Severity. Am J Ophthalmol. 2020 Nov;219:87-100.
`
`Strampe MR, Huckenpahler AL, Higgins BP, Tarima S, Visotcky A, Stepien KE, Kay CN, Carroll J.
`Intraobserver Repeatability and Interobserver Reproducibility of Ellipsoid Zone Measurements in Retinitis
`Pigmentosa. Transl Vis Sci Technol. 2018 Jun 4;7(3):13
`
`Dedania VS, Ghodasra DH, Kay CN, Roseman R, Johnson MW. CILIOCHOROIDAL EFFUSION AND
`ACUTE MACULAR NEURORETINOPATHY ASSOCIATED WITH CERVICAL TRACTION THERAPY.
`Retin Cases Brief Rep. 2018 Winter;12(1):24-28.
`
`Langlo, C.S., Erker, L.R., Parker, M., Patterson, E.J., Higgins, B.P., Summerfelt, P., Razeen, M.M., Collison,
`F.T., Fishman, G.A., Kay, C.N., Zhang, J., Weleber, R.G., Yang, P., Pennesi, M.E., Lam, B.L., Chulay, J.D.,
`Dubra, A., Hauswirth, W.W., Wilson, D.J., Carroll, J., ACHM-001 Study Group. Repeatability and
`longitudinal assessment of foveal cone structure in CNGB3-associated achromatopsia. Retina. 2017 Jan 31.
`doi: 10.1097/IAE.0000000000001434.
`
`Sun LW, Johnson RD, Langlo CS, Cooper RF, Razeen MM, Russillo MC, Dubra A, Connor TB Jr, Han DP,
`Pennesi ME, Kay CN, Weinberg DV, Stepien KE, Carroll J. Assessing Photoreceptor Structure in Retinitis
`Pigmentosa and Usher Syndrome. Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2428-42.
`
`Langlo C.S., Patterson E.J., Higgins B.P., Summerfelt P., Razeen M.M., Erker L.R., Parker M., Collison F.T.,
`
`
`8
`
`Celltrion Exhibit 1003
`Page 8
`
`

`

`December 6, 2023
`
`Fishman G.A., Kay C.N., Zhang J., Weleber R.G., Yang P., Wilson D.J., Pennesi M.E., Lam B.L., Chiang J.,
`Chulay J.D., Dubra A., Hauswirth W.W., Carroll J., ACHM-001 Study Group. Residual foveal cone structure
`in CNGB3-associated achromatopsia. Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):3984-95. doi:
`10.1167/iovs.16-19313.
`
`Sun LW, Johnson RD, Langlo CS, Cooper RF, Razeen MM, Russillo MC, Dubra A, Connor TB Jr, Han DP,
`Pennesi ME, Kay CN, Weinberg DV, Stepien KE, Carroll J. Assessing Photoreceptor Structure in Retinitis
`Pigmentosa and Usher Syndrome. Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2428-42. doi: 10.1167/iovs.15-
`18246.
`
`Dedania VS, Ghodasra DH, Kay CN, Roseman R, Johnson MW. "Ciliochoroidal Effusion and Acute Macular
`Neuroretinopathy Associated with Cervical Traction Therapy.” Accepted to Retina Cases and Brief Reports.
`
`Choi C, Zhang L, Abramoff MD, Sonka M, Shifera A, Kay CN. Evaluating Efficacy of Aflibercept in
`Refractory Exudative Age-Related Macular Degeneration with OCT segmentation volumetric analysis.
`Ophthalmic Surgery Lasers and Imaging. 2016 Mar 1;47(3):245-51
`
`Shifera AS, Kay CN. Early-onset X-linked retinitis pigmentosa in a heterozygous female harboring an
`intronic donor splice site mutation in the retinitis pigmentosa GTPase regulator gene. Ophthalmic Genetics.
`2015;36(3):251-6. doi: 10.3109/13816810.2013.879597.
`
`Chen JJ, Sohn EH, Mahajan VM, Kay CN, Boldt HC, Folk JC, Russell SR. “Response of Foveal Cystoid
`Changes from Idiopathic Juxtafoveal Telangiectasia to Carbonic Anhydrase Inhibitors.” Retina. 2014
`Jul;34(7):1400-6.
`
`Bhullar SS, Gray MJ, Kay CN. “Role for rapid surgical intervention in uveal effusion syndrome with
`associated optic neuropathy.” Ophthalmic Surg Lasers Imaging Retina. 2014 Apr 4;45(3):e11-3. doi:
`10.3928/23258160-20140331-04.
`
`Cohen J, Bhullar S, Kasuga D, Boye S, Elhalis H, Kay CN. “Retinal pigment epithelial detachment in ABCA4-
`associated Stargardt disease.” Ophthalmic Surgery Lasers and Imaging. 2013 Jul 1;44(4):401-4.
`
`Kay CN, Ryals RC, Aslanidi GV, Min SH, Ruan Q, Dyka FM, Kasuga D, Ayala AE, Van Vliet K, Agbandje-
`McKenna M, Hauswirth WW, Boye SL, Boye SE. “Targeting Photoreceptors Via Intravitreal Delivery Using
`Novel, Capsid-Mutated AAV Vectors.” PLoS One 2013 Apr 26;8(4):e62097.
`
`Bhalla S, Joshi D, Bhullar S, Kasuga D, Park Y, Kay CN. Long term follow-up data for efficacy and safety of
`treatment of retinitis pigmentosa with valproic acid.” British Journal Ophthalmology 2013 Jul;97(7):895-9.
`
`Hollsten JE, McClintock M, Samy H, Peden M, Kay CN. “Fulminant chorioretinitis and papillitis secondary
`to coxsackievirus B virus presenting as acute posterior multifocal placoid pigment epitheliopathy with
`positive response to IVIG.” Accepted to Retina Cases and Brief Reports.
`
`McClintock M, Peden MC, Kay CN. “Spectral domain optical coherence tomography findings in siblings
`with CNGB3-associated achromatopsia.” Adv. Exp. Med. Biol 2014;801:551-7.
`
`Boye SL, Peshenko IV, Huang WC, Min SH, McDoom I, Kay CN, Liu X, Dyka FM, Foster TC, Umino Y,
`Karan S, Jacobson SG ,Baehr W, Dizhoor A, Hauswirth WW and Boye SE. “AAV-mediated gene therapy in
`the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosis." Hum
`Mol Gene Therapy 2013 Feb;24(2):189-202.
`
`
`9
`
`Celltrion Exhibit 1003
`Page 9
`
`

`

`December 6, 2023
`
`
`Russell SR, Sohn EH, Boldt HC, Folk JC, Tarantola RM, Kay CN, Mahajan VM. “Elimination of infusion
`bubbles and uncontrolled reflux in the Alcon constellation vitrectomy vision system.” Retina 2013
`Apr;33(4):803-6.
`
`Kay CN, Quiram P, Mahajan VM. “23-Gauge Pediatric Vitrectomy using Limbus-based Trocar-Cannulas.”
`Retina. 2012 May;32(5):1023-7.
`
`Kay CN, Abramoff MD, Mullins RF, Kinnick TR, Lee K, Chung MM, Sohn EH, Stone EM. “Three
`dimensional distribution of the vitelliform lesion, photoreceptors, and retinal pigment epithelium in the
`macula of patients with Best vitelliform macular dystrophy.” Arch Ophthalmol. 2012 Mar;130(3):357-64.
`
`Kay CN, Pavan PR, Small LB, Zhang T, Zamba GKD, Cohen SM. “Familial Trends in a Population with
`Macular Holes.” Retina. 2012 Apr;32(4):754-9.
`
`Kay CN, Tarantola RM, Gehrs KM, Folk JC, Mahajan VB, Boldt HC, Syed N, Russell SR. “Uveitis Following
`Intravitreal Bevacizumab Injection: A Non-Infectious Cluster.” Ophthalmic Surgery Lasers and Imaging. 2011
`Jul-Aug;42(4):292-6.
`
`Kay CN, Elkins KA, Folk JC. “Resolution of refractory macular edema due to branch retinal vein occlusion
`after Ozurdex implantation.” Retina Cases and Brief Reports. 2012 Winter;6(1):72-5. doi:
`10.1097/ICB.0b013e3182051feb
`
`Kinnick TR, Mullins RF, Dev S, Leys M, Mackey D, Kay CN, Lam BL, Fishman GA, Traboulsi E, Stone EM.
`“Autosomal Recessive Vitelliform Macular Dystrophy in a Large Cohort of Vitelliform Macular Disease
`Patients.” Retina. 2011 Mar;31(3):581-95.
`
`Tarantola RM, Elkins KA, Kay CN, Folk JC. “Photoreceptor Recovery Following Laser Photocoagulation and
`Albendazole in Diffuse Unilateral Subacute Neuroretinitis.” Arch Ophthalmol. 2011 May;129(5):669-71.
`
`Kay CN, Saunders T, Pavan PR. “Ocular Injuries Sustained in Paintball Trauma.” Graefe’s Archive for Clinical
`and Experimental Ophthalmology 2010 Mar;248(3):331-2.
`
`Potcoava M, Kay CN, Kim MK, Richards DW. “In vitro imaging of ophthalmic tissue by digital interference
`holography.” Journal of Modern Optics 2009.
`
`Kay CN, Pavan PR, Burrows A, Martino AZ. "Neurosensory Retinal Detachment of the Macula in Retinal
`Phototoxicity Documented by Optical Coherence Tomography." Retinal Cases and Brief Reports. 2010
`Spring;4(2):143-5. doi: 10.1097/ICB.0b013e3181997ce7.
`
`Kay CN, Gendy MG, Lujan BJ, Punjabi OS, Gregori G, Flynn HW. “Composite Spectral Domain Optical
`Coherence Tomography Images of Diabetic Tractional Retinal Detachment.” Ophthalmic Surgery Lasers and
`Imaging 2008; 39:S99-S103.
`
`(Kay) Nichols C, Pincus DW, Bhatti MT. "Optociliary Shunt Vessels." Neurology 64: 1443. April 2005.
`
`[Submitted & In Preparation]
`Margaret R. Strampe, Alison L. Huckenpahler, Mr. Brian P. Higgins , Kimberly E. Stepien , Dr. Christine N. Kay, Joseph
`Carroll. Repeatability of ellipsoid zone measurements in retinitis pigmentosa. Submitted to TVST.
`
`
`
`10
`
`Celltrion Exhibit 1003
`Page 10
`
`

`

`December 6, 2023
`
`Min SH, Boye SL, Ryals RC, Ruan Q, Sun J, Dyka F, Hauswirth WW, Boye SE, Kay CN. Long-term
`restoration of visual function in the CNGB3/NRL double knockout mouse, a cone-dominant model of
`CNGB3-achromatopsia. In preparation.
`
`PUBLICATIONS (invited authorship/non peer-reviewed)
`
`Kay CN. Subretinal Gene Therapy Delivery. (Book Chapter, Operative Techniques in Vitreoretinal Surgery.)
`2020.
`
`Kay CN, Boye S and Boye SE. Clinical In Vivo Gene Therapy (Ocular Disorders.) Molecular Therapy. 2020
`
`Kay CN. Retinal Gene Therapies in Clinical Trials: A proliferation of clinical trials means hope for patients.
`Retinal Physician, March 2019.
`
`Kay CN. “Logistics of Genetic Testing: An Overview for Retina Specialists.” Retinal Physician. November
`2017.
`
`Kay CN. “Gene Therapy: The new frontier for inherited retinal disease.” Retina Specialist. March 2017.
`
`Hu JK, Griffeth W, Kay CN. “Interview with Dr. Robert MacLaren on clinical implications of his landmark
`study on retinal gene therapy in patients with choroideremia.” ASRS publication 2014, invited editorial.
`
`Kay CN, Joshi S, Gallagher P. “Ocular infection and inflammation: UVEITIS.” Focus-ED CME publication.
`Editors: Slonim CB, Raizman MA, Eichenbaum DA. Vol 1, Issue 2, Winter 2009.
`
`Kay CN, Sohn E, Abramoff MD. “Biomarkers in Retinal Disease.” Retinal Physician.
`
`BOOK CHAPTERS
`Co-author on chapter on Image Analysis with Dr. Michael Abramoff: Retina, 5th ed., Editor Stephan Ryan.
`
`
`PRESENTATIONS AT NATIONAL MEETINGS
`
`[Oral Presentations]
`
`Kay CN et al. ALK-001 (C20-D3-Vitamin A) Slows the Growth of Atrophic Lesions in ABCA4-Related Stargardt
`Disease: Results of a Randomized, Placebo-Controlled Clinical Trial, the TEASE Study. AAO Subspecialty Day
`2023
`
`Kay CN et al. MCO-010 optogenetic vision restoration in retinitis pigmentosa patients with profound vision
`loss: A randomized, sham-controlled, multi-center, double-masked clinical trial (RESTORE). Retina Society
`2023
`
`Kay CN et al. A Phase 1/2 Clinical Trial Evaluating 4D-150, a Dual-transgene Intravitreal Gene Therapy in
`Patients with Wet Age-Related Macular Degeneration: Interim 9 Month Results. ASRS 2023
`
`Kay CN et al. “Safety and Efficacy of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by
`Biallelic Mutations in GUCY2D (LCA1). Macula Society 2023
`
`
`
`11
`
`Celltrion Exhibit 1003
`Page 11
`
`

`

`December 6, 2023
`
`Kay CN et al. “Safety and Efficacy of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by
`Biallelic Mutations in GUCY2D (LCA1). Retina Subspecialty Day, AAO 2022
`
`Kay CN et al. ALK-001 (C20-D3-Vitamin A) Slows the Growth of Atrophic Lesions in ABCA4-Related Stargardt
`Disease: Results of a Randomized, Placebo-Controlled Clinical Trial, the TEASE Study, AAO 2022
`
`Kay CN et al. Qualitative experience of patients and caregivers regarding visual functions and impacts on
`vision depending activities of daily living and health related quality of life in RPE65-related RP and LCA.
`ARVO 2021 (virtual due to COVID).
`
`Kay CN et al. “Patient and caregiver experiences of functional vision impairment and health-related quality of life
`limitations associated with hereditary retinitis pigmentosa.” Paper presentation (virtual due to COVID), ARVO 2020
`
`Kay CN. “Suprachoroidal delivery for ocular gene therapy: nonclinical experiments evaluating non-viral
`DNA nanoparticles.” AAO 2019.
`
`Kay CN. “Complement C5 Inhibition as a Potential Treatment for Autosomal Recessive Stargardt Disease
`(STGD1): Design of a Clinical Trial Assessing a Novel Treatment and Primary Outcome Measure”
`(Ophthotech trial). Macula Society, Feb 2019.
`
`Kay CN. "Phase 2 Tolerability and Effects of ALK-001 in Stargardt Disease ("TEASE" Trial): An Update.”
`Macula Society, Feb 2018.
`
`Kay CN. "Phase 2 Tolerability and Effects of ALK-001 in Stargardt Disease ("TEASE" Trial): An Update.”
`Retina Society, Boston 2017.
`
`Kay CN. "Phase 2 Tolerability and Effects of ALK-001 in Stargardt Disease ("TEASE" Trial): An Update.”
`ASRS Boston 2017.
`
`Kay CN, Hu J. Angiographic reperfusion of choroidal occlusion and associated recovery in visual acuity and
`field after rapid anticoagulation. IVFA conference at ASRS, San Diego CA 2014.
`
`Kay CN and Bhalla S. Long-term efficacy and safety of treatment of retinitis pigmentosa with
`valproic acid. ASRS 2013.
`
`Kay CN and Bhalla S. Long-term efficacy and safety of treatment of retinitis pigmentosa with
`valproic acid. ARVO 2013.
`
`Kay CN, Hollsten J, McClintock, Peden M, Samy H. “A case of fulminant bilateral chorioretinitis
`and papillitis.” American Society of Retina Specialists: Las Vegas, Nevada; 2012.
`
`Kay CN, Joshi D, Gray M. Uveal effusion syndrome with associated anterior ischemic optic
`neuropathy with dramatic improvement after scleral windows procedure.” American Society of
`Retina Specialists: Las Vegas, Nevada; 2012.
`
`Russell SR, Mahajan VB, Boldt HC, Folk JC, Sohn EH, Kay CN, Tarantola RM. “Constellation 2.0:
`Eliminating Infusion Bubbles and Uncontrolled Reflux.” Retina Society Meeting: Rome, Italy; 2011
`
`Kay CN, Mullins RF, Kinnick T, Stone EM. “Morphology of the Vitelliform Lesion in Best Disease.”
`
`
`
`12
`
`Celltrion Exhibit 1003
`Page 12
`
`

`

`December 6, 2023
`
`American Society of Retina Specialists: Vancouver, Canada; August 2010.
`
`Kay CN, Tarantola RM, Folk JC. Fluorescein case conference: “DUSN.” American Society of Retina
`Specialists: Vancouver, Canada; August 2010.
`
`Folk JC, Stone EM, Kay CN, et al. “Molecular Genetics of AMD and its response to treatment.” Paper
`presentation at 28th annual meeting of American Society of Retina Specialists, Vancouver, Canada; August
`2010.
`
`Potcoava M, Kay CN, Kim MK, Richards DW. “Digital Interference Holography in Ophthalmology.” ARVO
`2008.
`
`
`Kay CN and Pavan PR. “Ocular injuries sustained in paintball trauma.” Free Paper Session. Fourth
`International Ophthalmologic School organized by Croatian Society for Cataract and Refractive Surgery.
`Croatia; May 2008.
`
`Kay CN, Potcoava M, Kim MK, Richards DW. “Digital Holography Imaging of Human Macula.” Paper
`Presentation. Florida Society of Ophthalmology Resident Symposium. Palm Beach, FL; June 2008.
`
`Kay CN, Cohen SM, Pavan PR, Small LB. “A family history study of macular holes.” Gass Society Meeting.
`Paper presentation. Honolulu, Hawaii; October 2008.
`
`Kay CN, Pavan PR, Kelty PJ. “Ocular injuries sustained in paintball trauma.” Paper presentation. American
`Society of Retina Specialists: Maui, Hawaii; October 2008.
`
`Kay CN, Pavan PR. “Case of Lupus causing peripheral neovascularization and tractional retinal
`detachments.” Grand Rounds presentation, Women in Retina Symposium, American Society of Retina
`Specialists: Maui, Hawaii; October 2008.
`
`Kay CN, Potcoava M, Kim MK, Richards DW. “Imaging of Human Optic Nerve with Digital Interference
`Holography.” Paper Presentation. Asia ARVO: Hyderabad, India: January 2009.
`
`Potcoava MC, Kim MK, Kay CN. “Wavelength scanning digital interference holography for high-resolution
`ophthalmic imaging.” SPIE 2009 BiOS Biomedical Optics Symposium 2009. Ophthalmic Technologies XIX,
`section 3-Ophthalmic Imaging Technology II . San Jose, CA. January 2009.
`
`
`[Courses at National Meetings]
`Kay CN (course organizing faculty) with co-faculty: Jacque L Duncan MD, Isabelle Audo , Ninel Z Gregori
`MD, Byron L Lam MD, Karmen M Trzupek MS, Janet Davis MD, Kimberly E Stepien MD, Mark E Pennesi
`MD PhD, Michel Michaelides, MD, Elliott H Sohn MD. AAO 2019. “Retinal Frontiers: Updates in Gene
`Therapy.”
`
`Kay CN (course organizing faculty) with co-faculty: Ninel Gregori, Benjamin Bakall, Janet Davis, Karmen
`Trzupek, Kimberly Stepien. Instructional course at ASRS 2019. “Retinal Gene Therapy:
`Genetic Testing, Viral Vectors, Surgical Delivery, and Clinical Trials.”
`
`Kay CN (course organizing faculty) with co-faculty: Jacque L Duncan MD, Isabelle Audo , Ninel Z Gregori
`MD, Byron L Lam MD, Karmen M Trzupek MS, David M Gamm MD, Kimberly E Stepien MD, Mark E
`
`
`
`13
`
`Celltrion Exhibit 1003
`Page 13
`
`

`

`December 6, 2023
`
`Pennesi MD PhD, Michel Michaelides, MD, Elliott H Sohn MD. AAO 2018. “Retinal Frontiers: Updates in
`Gene Therapy and Stem Cell Therapy.”
`
`Kay CN (course organizing faculty) with co-faculty: Ninel Gregori, Benjamin Bakall, Elliott Sohn, Karmen
`Trzupek, Instructional course at ASRS 2018. “Retinal Gene Therapy: Clinical and Surgical Overview.”
`
`Kay CN (course organizing faculty) with co-faculty: Jacque L Duncan MD, Isabelle Audo , Ninel Z Gregori
`MD, Byron L Lam MD, Karmen M Trzupek MS, David M Gamm MD, Kimberly E Stepien MD, Mark E
`Pennesi MD PhD, Michel Michaelides, MD, Elliott H Sohn MD. AAO 2017. “Retinal Frontiers: Updates in
`Gene Therapy and Stem Cell Therapy.”
`
`Kay CN (course organizing faculty) with co-faculty: Ninel Gregori, Benjamin Bakall, Elliott Sohn, Janet
`Davis, Instructional course at ASRS 2017. “Retinal Gene Therapy: Clinical and Surgical Overview.”
`
`Huang S, Kay CN, Maguire A, Humayun M, Kashani A, Duker J, Eliott D. “Future Therapies” instructional
`course, ASRS 2017.
`
`Kay CN (course organizing faculty) with co-faculty: Jacque Duncan, Kimberly Stepien, Benjamin Bakall,
`Ninel Gregori, Janet Davis, Karmen Trpuzek. Instructional course at ASRS 2016. “A genetic approach to
`inherited retinal dystrophies: clinical classification of common retinal dystrophies, genotyping, and gene
`therapy.”
`
`Kay CN (course organizing faculty) with co-faculty: Jacque Duncan J, Byron Lam, Sandeep Grover, Kimberly
`Stepien, Isabelle Audo, Ninel Gregory, Karmen Trpuzek. Instructional course at AAO 2016. “A genetic
`approach to inherited retinal dystrophies: clinical classification of common retinal dystrophies, genotyping,
`and gene therapy.”
`
`Kay CN (course organizing faculty) with co-faculty: Duncan J, Lam B, Pennesi M, Michaelides M, Sohn E,
`Audo I. Instructional course at AAO 2015. “A genetic approach to inherited retinal dystrophies: clinical
`classification of common retinal dystrophies, genotyping, and gene therapy.”
`
`Kay CN (course organizing faculty) with co-faculty: Duncan J, Lam B, Pennesi M, Michaelides M, Sohn E,
`Audo I. Instructional course at AAO 2014. “A genetic approach to inherited retinal dystrophies: clinical
`classification of common retinal dystrophies, genotyping, and gene therapy.”
`
`Kay CN and Bakall B. Instructional course: A genetic approach to inherited retinal dystrophies: updates on
`clinical classification of common retinal dystrophies, genotyping, and gene therapy. ASRS 2014 San Diego.
`
`Kay CN and Sohn E. Instructional course: A genetic approach to inherited retinal dystrophies: updates on
`clinical classification of common retinal dystrophies, genotyping, and gene therapy. ASRS 2013, Toronto.
`
`
`
`[Poster Presentations]
`Decarlo D, Nowakowski R, Kay CN. "RPE65 Associated Leber Congenital Amaurosis – Phenotype and
`Treatment.” American Academy of Optometry. 2019.
`
`Banhazi J, Williamson N, Bradley H, Exall E, Naujoks C, Spera C, Green J, Fischer MD, Audo I, Kay C,
`Viriato D. “What do we know ab